Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Initiates Coverage On TaskUs with Outperform Rating

Baird analyst David Koning initiates coverage on TaskUs (NASDAQ:TASK) with a Outperform rating.

byBenzinga Newsdesk

July 6, 2021

1 minute read

Baird analyst David Koning initiates coverage on TaskUs (NASDAQ:TASK) with a Outperform rating.

Read Why Truist Slashed NVIDIA Price Target By 10%

By Anusuya Lahiri

Today, 2:52 AM

Truist analyst William Stein lowered the price target on NVIDIA Corp (NASDAQ:NVDA) to $350 from $389 but kept a Buy rating on the…

NVDA

Truist Securities Maintains Buy on Camden Prop Trust, Lowers Price Target to $149

By Benzinga Newsdesk

Today, 2:52 AM

Truist Securities analyst Michael Lewis maintains Camden Prop Trust (NYSE:CPT) with a Buy and lowers the price target from $160 to $149.

CPT

The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales

By Shanthi Rexaline

Today, 2:52 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ABBV

Phunware Now Accepts Bitcoin For Lyte Personal Computers

By Benzinga Newsdesk

Today, 2:52 AM

Phunware, Inc. (NASDAQ:PHUN) (the "Company"), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, announced

PHUN

Baird Initiates Coverage On TaskUs with Outperform Rating

Related Posts

Read Why Truist Slashed NVIDIA Price Target By 10%

Truist Securities Maintains Buy on Camden Prop Trust, Lowers Price Target to $149

The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales

Phunware Now Accepts Bitcoin For Lyte Personal Computers